Rearrangement of the myeloid/lymphoid Leukemia Gene in therapy-related myelodysplastic syndrome in patients previously treated with agents targeting DNA topoisomerase II

Oncology (Switzerland)

Volumn 83, Issue 3, 2012, Pages 128-134

  Mosad, Eman ^a   Abdou, Madleen ^b   Zaky, Amen Hamdy ^a,b  

^a Assiut University Faculty of Medicine   (Egypt)

^b ASSIUT UNIVERSITY   (Egypt)

Author keywords

Myeloid lymphoid leukemia gene rearrangement; Therapy related myelodysplastic syndrome; Topoisomerase II inhibitors

Indexed keywords

BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; GYRASE INHIBITOR; IFOSFAMIDE; MESNA; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; MIXED LINEAGE LEUKEMIA PROTEIN; PIRARUBICIN; PLATINUM DERIVATIVE; PREDNISONE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; ARTICLE; BONE MARROW BIOPSY; CHROMOSOME 11Q; CHROMOSOME TRANSLOCATION 11; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FREQUENCY; GENE REARRANGEMENT; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; RETROSPECTIVE STUDY;

ADULT; AGED; FEMALE; GENE REARRANGEMENT; HODGKIN DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEUROBLASTOMA; RETROSPECTIVE STUDIES; TOPOISOMERASE II INHIBITORS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84863877162     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000338769     Document Type: Article

References (30)

1. Valagussa P, Santoro A, Fossati-Bellani F, Banfi A, Bonadonna G: Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986;4:830-837. (Pubitemid 16080935)
2. Pedersen-Bjergaard J, Specht L, Larsen SO, Ersbøll J, Struck J, Hansen MM, Hansen HH, Nissen NI: Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 1987;2:83-88. (Pubitemid 17090517)
3. Rowley JD, Golomb HM, Vardiman JW: Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease. Blood 1981;58:759-767. (Pubitemid 11015833)
4. Whang-Peng J, Young RC, Lee EC, Longo DL, Schechter GP, DeVita VT Jr: Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 1988;71:403-414. (Pubitemid 18089529)
5. Le Beau MM, Albain KS, Larson RA, et al: Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes No. 5 and 7. J Clin Oncol 1986;4:325-345. (Pubitemid 16133086)
6. Johansson B, Mertens F, Heim S, et al: Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL). Eur J Haematol 1991;47:17-27.
7. Pedersen-Bjergaard J, Pedersen M, Roulston D, et al: Different genetic pathways in leukemogenesis for patients presenting with therapyrelated myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995;86:3542-3552.
8. Ratain MJ, Kaminer LS, Bitran JD, et al: Acute non-lymphocytic leukaemia following etoposide and cisplatin combination chemotherapy for advanced non-small cell carcinoma of the lung. Blood 1987;70:1412-1417. (Pubitemid 18026147)
9. Pui CH, Behm FG, Raimondi SC, et al: Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. N Engl J Med 1989;321:136-142. (Pubitemid 19180676)
10. DeVore R, Whitlock J, Hainsworth JD, et al: Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q. Ann Intern Med 1989;110:740-742. (Pubitemid 19121232)
11. Pedersen-Bjergaard J, Philip P: Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II. Blood 1991;78:1147-1148.
12. Larson RA, Le Beau MM, Ratain MJ, et al: Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia. Blood 1992;79:1892-1893.
13. Arana-Yi C, Block AMW, Sait SN, Ford LA, Barcos M, Baer MR: Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine. Leuk Res 2008;32:1043-1048.
14. Bloomfield CD, Archer KJ, Mrózek K, Lillington DM, Kaneko Y, Head DR, Dal Cin P, Raimondi D, Boyett J, Rubnitz JE, Gajjar A, Raimondi S, Chauncey TR, Rankin C, Anderson JE, Chen I, Kopecky KJ, Godwin JE: 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33:362-378. (Pubitemid 34208798)
15. Papenhausen PR, Griffin S, Tepperberg J: Oncogene amplification in transforming myelodysplasia. Exp Mol Pathol 2005;79:168-175. (Pubitemid 41262499)
16. Hayato T, Hiroki Y, Hiroyuki H, Fumiharu Y, Masami B, Takeshi K, Hideki A, Hisashi S, et al: Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a cooperative multicenter study. Int J Hematol 2008;87:195-202.
17. Byrd JC, Mrozek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from cancer and leukemia group B (CALGB 8461). Blood 2002;100:4325-4326.
18. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 Trial. Blood 1998;92:2322-2333. (Pubitemid 28452973)
19. Mauritzson N, Albin M, Rylander L, Billstrom R, Ahlgren T, Mikoczy Z, et al: Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed in 1993 and on 5, 098 unselected cases reported in the literature. Leukemia 2002;16:2366-2378. (Pubitemid 36067289)
20. Passmore SJ, Chessells JM, Kempski H, Hann IM, Brownbill PA, Stiller CA: Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival. Br J Haematol 2003;121:758-767. (Pubitemid 36718192)
21. Bader-Meunier B, Mielot F, Tchernia G, Buisine J, Delsol G, Duchayne E, et al: Myelodysplastic syndromes: report of 49 patients from a French multicentre study. Br J Haematol 1996;92:344-350. (Pubitemid 26042931)
22. Pui CH, Relling MV: Topoisomerase II inhibitorrelated acute myeloid leukemia. Br J Haematol 2000;109:13-23. (Pubitemid 30340574)
23. Pedersen-Bjergaard J, Andersen Mette K, Christiansen Debes H, Nerlov C: Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood J 2002;99:1909-1912. (Pubitemid 34525468)
24. Felix CA: Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998;1400:233-255. (Pubitemid 28475107)
25. Le H, Singh S, Shih S-J, Du N, Schnyder S, Loredo GA, Bien C, Michaelis L, Toor A, Diaz M, Vaughan AT: Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topo isomerase II binding. Genes Chromosomes Cancer 2009;48:806-815.
26. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T: Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004;18:120-125. (Pubitemid 38159447)
27. Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung N-KV: Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 2004;22:4888-4892. (Pubitemid 46638612)
28. Bernt KM, Armstrong SA: targeting epigenetic programs in MLL-rearranged hematology. Am Soc Hematol Educ Program 2011;2011:354-360.
29. Libura PA, Richardson J, Richardson C: Etoposide and illegitimate DNA doublestrand break repair in the generation of MLL translocations: new insights and new questions. DNA Repair 2006;5:1109-1118. (Pubitemid 44291612)
30. Hake CR, Graubert TA, Fenske TS: Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? Bone Marrow Transplant 2007;39:59-70. (Pubitemid 46085225)